Brazilian health regulator Anvisa said on Monday it had certified the production standards of CoronaVac, China’s Sinovac-produced coronavirus vaccine candidate, which is being tested in Brazil, reported Reuters. The certificate of good standards to Sinovac’s factory in China was anticipated by Anvisa by 10 days.
Anvisa has certified the quality of Sinovac’s production standards, not the vaccine itself. The certification is essential both for definitive approval and for the emergency use of the vaccine. Brazil’s Sao Paulo state has said it will announce on Wednesday if CoronaVac has been found to be effective against the coronavirus. On Thursday Butantan Institute should receive more than 5.5 million doses of the CoronaVac vaccine.
According to the Wall Street Journal, Sinovac Biotech‘s has shown efficacy rate higher than 50% in late-stage trials in Brazil, citing unnamed sources involved in the vaccine’s development.
However, Butantan Institute, the Brazilian public health entity handling trials for a COVID-19 vaccine developed by China’s Sinovac Biotech said in a note after WSJ report that any statements on the efficacy of the shot before its December 23 announcement were “mere speculation.”